Product Description
The research-grade biosimilar is a human IgG1 lambda monoclonal antibody that specifically targets programmed death-ligand 1 (PD-L1). Binding of PD-L1 to the PD-1 and B7.1 receptors occurs on T cells and antigen-presenting cells that results in suppression of cytotoxic T-cell activity, T-cell proliferation, and cytokine production. The antibody binds PD-L1 through the FG loops and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This releases the suppression of immune responses and promotes the inhibition of tumor growth. Studies show that the drug is capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. The original drug received FDA approval to treat Merkel cell cancer. It is currently been used in immunotherapy for several cancers
Biovision | A2152 | Anti-PD-L1 (Avelumab), Human IgG1 Antibody DataSheet
Antibody Target: PD-L1
Target Alternative Name: MSB-0010718C, MSB0010682, B7-H, B7H1, B7-H1, CD274, PDCD1L1, PDL1, PD-L1, B7 homolog 1, PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
Tag Line: The biosimilar is a human IgG1 lambda monoclonal antibody that binds to PD-L1 and inhibits the interaction with PD-1 and promotes anti-tumor immune response
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, lambda
Species Reactivities: Human
Immunogen Sequence: Human PD-L1
Accession #: DB11945
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE